• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 and Women’s Health

More Evidence that Fertility is Unaffected by COVID-19 Vaccination

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Hillson et al. (The Lancet, 2021) assessed pregnancy outcomes for women who received AstraZeneca’s COVID-19 vaccine during the clinical trials

METHODS:

  • Secondary analysis of phase 1, phase 2 and phase 3 clinical vaccine trials | In primary trials, pregnant women were excluded from trials
  • Participants
    • ≤49 years
  • Interventions
    • Vaccination with AstraZeneca (ChAdOx1)
    • Placebo          
  • Study design
    • Pregnancies that occurred during the trial were follow-up until 3 months after birth
  • Primary outcomes
    • Fertility rate: Based upon number of pregnancies and number of viable pregnancies
    • Miscarriage: Defined as pregnancy loss <23 weeks

RESULTS:

  • 9755 participants included in vaccine trials
    • Pregnancy reported during trial: 1%
    • Fertility outcome analysis: 93 participants
      • Received ChAdOx1: 50
      • Received placebo: 43
    • Pregnancy outcome analysis: 107 participants
      • Received ChAdOx1: 72
      • Received placebo: 35
    • Baseline characteristics were similar between vaccine and control groups
  • There was no evidence of reduced fertility with ChAdOx1 vaccination
    • Fertility rate ratio (pregnancies): 1.14 (95% CI, 0.76 to 1.71); P=0.53
    • Fertility rate ratio (viable pregnancies): 1.08 (95% CI, 0.66 to 1.79); P=0.80
  • The rate of miscarriage in the vaccine group was no different from that in the control group
    • Miscarriage risk ratio: 0.67; P=0.51

CONCLUSION:

  • There is no evidence that the ChAdOx1 COVID-19 vaccine is associated with decreased fertility or increased rate of miscarriage
  • The authors state

With increasing availability of misinformation, which continues to affect vaccine uptake, these data, along with published data on mRNA vaccines, can provide evidence to support women in making decisions regarding vaccination

Learn More – Primary Sources:

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 and Women’s Health Posts
Next >

Related ObG Topics:

COVID-19 Vaccination and Miscarriage: Another Study Finds No Link
Is There Any Evidence of a Link Between COVID-19 Vaccines and Spontaneous Abortion?
mRNA COVID-19 Vaccine Safety in Pregnant Women
Do Menstrual Cycle Changes Occur Following SARS-CoV-2 Infection?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site